Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Breast Neoplasms 2Ventricular Dysfunction, Left 1Lymphoma, Large B-Cell, Diffuse 1Cardiotoxicity 1

Interventions

Echocardiography 14Doxorubicin 10Exercise 8Electrocardiography 7Trastuzumab 6Cyclophosphamide 5Carvedilol 5Docetaxel 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Magnetic Resonance Spectroscopy 2Ivabradine 2High-Intensity Interval Training 2Exercise Test 2Chemoradiotherapy 2Blood Specimen Collection 2Bisoprolol 2Antineoplastic Agents 2Anthracyclines 2sulforaphane 1schizandrin 1pegfilgrastim 1nicotinamide-beta-riboside 1mitoquinone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cardiotoxicity × Nebivolol × Clear all
NCT05728632 2023-02-23

CONTROL

Humanitas Hospital, Italy

Phase 3 Unknown
80 enrolled
BreastLymphoid

Breast Neoplasms, Lymphoma, Large B-Cell, Diffuse, Ventricular Dysfunction, Left, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡